RARE

Ultragenyx is a real commercial biopharma, not a pre-revenue story: four approved products (Crysvita, Mepsevii, Dojolvi, Evkeeza) drove FY2025 revenue to $673M, up 20.2% YoY and more than double FY2021's $351M. That top-line durability is the bull case. But the income statement and balance sheet tell the deciding story. Net loss was $575M in FY2025 — essentially flat vs. FY2024's $569M — meaning four straight years of ~$575M-$700M losses with no path to breakeven visible in the numbers. Operating margin is -79.5% and net margin -85.4%. Critically, R&D alone ($750M) exceeds total revenue ($673M), so every dollar of incremental sales is being out-spent on the pipeline; revenue growth is not translating into operating leverage.

The balance sheet has crossed an inflection that warrants the 'avoid' label rather than 'sell.' Stockholders' equity is now negative (-$80M, down 131% YoY) as total liabilities jumped 29.3% to $1.60B against $1.53B of assets, and the accumulated deficit sits at -$4.53B. Liabilities/equity of -20.06x is a symptom of that hole. Management discloses $737M in available cash, equivalents and marketable securities, but operating cash flow was -$466M and worsening (-12.6% YoY). That implies roughly 18 months of runway before a raise is required — and the MD&A and Risk Factors say so plainly: 'We may need to raise additional capital to fund our activities' and 'We have a history of operating losses and expect to continue to incur operating losses.' Shares already grew 4.5% YoY; further dilution at a depressed $30.68 price (a $2.96B cap) is the most likely funding path and is a direct headwind to per-share value.